Kathleen Moore to Fallopian Tube Neoplasms
This is a "connection" page, showing publications Kathleen Moore has written about Fallopian Tube Neoplasms.
Connection Strength
3.364
-
Niraparib in the treatment of previously treated advanced ovarian, fallopian tubeĀ or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
Score: 0.668
-
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
Score: 0.631
-
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648.
Score: 0.605
-
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
Score: 0.578
-
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403.
Score: 0.275
-
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol. 2019 04; 83(4):717-726.
Score: 0.149
-
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505.
Score: 0.147
-
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290.
Score: 0.135
-
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):204-9.
Score: 0.120
-
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005 May; 192(5):1614-9.
Score: 0.058